51. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
- Author
-
Iudici, M., Pantano, I., Fasano, S., Pierro, L., Charlier, B., Pingeon, M., Dal Piaz, F., Filippelli, A., and Izzo, V.
- Subjects
SYSTEMIC lupus erythematosus treatment ,SYSTEMIC lupus erythematosus ,IMMUNOSUPPRESSIVE agents ,QUALITY of life ,FATIGUE (Physiology) ,PATIENTS - Abstract
Background/objective: The objectives of this paper are to assess the extent of and the factors associated with hydroxychloroquine (HCQ) non-adherence in systemic lupus erythematosus (SLE) patients with prolonged inactive disease and to investigate relationships between blood HCQ concentration and quality of life (QoL). Methods: Consecutive SLE patients, in remission for at least one year and taking a stable dose of HCQ were investigated. At study entry (T0) and six months later (T6) a blood venous sample was taken to measure whole blood concentration of [HCQ] and desethylchloroquine ([DCQ]). Moreover, at T0 each patient completed validated questionnaires assessing QoL, disability, anxiety, depression and visual analogue scales for fatigue, pain, general health (GH), and self-assessment of disease activity. Results: Eighty-three patients with a median [HCQ] of 327 ng/ml were enrolled. At T0, 24 (29%) were defined as non-adherent ([HCQ]<100 ng/ml). At multiple logistic regression analysis the physical summary of SF-36 (p=0.038), and the concomitant use of immunosuppressants (p=0.010) were independently associated with non-adherence. A significant increase of HCQ adherence was observed at T6 (p<0.05). Conclusions: A better health status and the concomitant prescription of immunosuppressants represent risk factors for HCQ non-adherence in SLE patients in remission. Monitoring HCQ levels might represent an important opportunity to improve adherence. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF